

John R Perfect

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6578919/john-r-perfect-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

252
papers

18,390
citations

59
h-index

134
g-index

280
ext. papers

21,963
ext. citations

7.1
avg, IF

6.86
L-index

#	Paper	IF	Citations
252	The emergence of COVID-19 associated mucormycosis: a review of cases from 18 countries.. <i>Lancet Microbe, The</i> , 2022 ,	22.2	34
251	Transcriptional Profiles Elucidate Differential Host Responses to Infection with <i>Cryptococcus neoformans</i> and <i>Cryptococcus gattii</i> . <i>Journal of Fungi (Basel, Switzerland)</i> , 2022 , 8, 430	5.6	0
250	Superiority of a Novel Mp1p Antigen Detection Enzyme Immunoassay Compared to Standard BACTEC Blood Culture in the Diagnosis of Talaromycosis. <i>Clinical Infectious Diseases</i> , 2021 , 73, e330-e336	11.6	12
249	Aortic Pseudoaneurysm Following Aortic Valve Replacement: Case Report and Review of the Literature.. <i>Open Forum Infectious Diseases</i> , 2021 , 8, ofab536	1	0
248	Gene Expression of Diverse <i>Cryptococcus</i> Isolates during Infection of the Human Central Nervous System. <i>MBio</i> , 2021 , e0231321	7.8	3
247	A global call for talaromycosis to be recognised as a neglected tropical disease. <i>The Lancet Global Health</i> , 2021 , 9, e1618-e1622	13.6	4
246	Inositol Metabolism Regulates Capsule Structure and Virulence in the Human Pathogen <i>Cryptococcus neoformans</i> . <i>MBio</i> , 2021 , e0279021	7.8	1
245	A randomized, double-blind, placebo-controlled clinical trial of fluconazole as early empiric treatment of coccidioidomycosis pneumonia (Valley Fever) in adults presenting with community-acquired pneumonia in endemic areas (FLEET-Valley Fever). <i>Contemporary Clinical Trials Communications</i> , 2021 , 24, 100851	1.8	1
244	MSG07: An International Cohort Study Comparing Epidemiology and Outcomes of Patients With <i>Cryptococcus neoformans</i> or <i>Cryptococcus gattii</i> Infections. <i>Clinical Infectious Diseases</i> , 2021 , 73, 1133-1141	11.6	5
243	Associations between Genotypes, Phenotypes, and Clinical Parameters of Human Disease: A Review. <i>Journal of Fungi (Basel, Switzerland)</i> , 2021 , 7,	5.6	14
242	Amoeba Predation of <i>Cryptococcus neoformans</i> Results in Pleiotropic Changes to Traits Associated with Virulence. <i>MBio</i> , 2021 , 12,	7.8	4
241	Reply to Day et al. <i>Journal of Infectious Diseases</i> , 2021 , 224, 1627-1628	7	1
240	Fab-dimerized glycan-reactive antibodies are a structural category of natural antibodies. <i>Cell</i> , 2021 , 184, 2955-2972.e25	56.2	22
239	Outcomes and Health Care Resource Utilization of Adult Bacterial Meningitis in the United States. <i>Neurology: Clinical Practice</i> , 2021 , 11, 117-126	1.7	0
238	Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. <i>Lancet Infectious Diseases, The</i> , 2021 , 21, e149-e162	25.5	242
237	Uncommon Yeasts and Molds Causing Human Disease 2021 , 813-834		2
236	Cryptococcal Antigen in Serum and Cerebrospinal Fluid for Detecting Cryptococcal Meningitis in Adults Living With Human Immunodeficiency Virus: Systematic Review and Meta-Analysis of Diagnostic Test Accuracy Studies. <i>Clinical Infectious Diseases</i> , 2021 , 72, 1268-1278	11.6	14

235	Paediatric bacterial meningitis in the USA: outcomes and healthcare resource utilization of nosocomial versus community-acquired infection. <i>Journal of Medical Microbiology</i> , 2021 , 70,	3.2	1
234	Comparison of / Species Complex to Related Genera (and) Reveal Variances in Virulence Associated Factors and Antifungal Susceptibility. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021 , 11, 642658	5.9	2
233	ECMM/ISHAM recommendations for clinical management of COVID-19 associated mucormycosis in low- and middle-income countries. <i>Mycoses</i> , 2021 , 64, 1028-1037	5.2	48
232	Global guideline for the diagnosis and management of rare yeast infections: an initiative of the ECMM in cooperation with ISHAM and ASM. <i>Lancet Infectious Diseases, The</i> , 2021 , 21, e375-e386	25.5	15
231	Cryptococcal meningoencephalitis: time for action. <i>Lancet Infectious Diseases, The</i> , 2021 , 21, e259-e271	25.5	5
230	Fungal Infections of the Central Nervous System 2021 , 803-819		
229	The virulence factor urease and its unexplored role in the metabolism of <i>Cryptococcus neoformans</i> . <i>FEMS Yeast Research</i> , 2020 , 20,	3.1	4
228	Clinical mycology today: A synopsis of the mycoses study group education and research consortium (MSGERC) second biennial meeting, September 27-30, 2018, Big Sky, Montana, a proposed global research agenda. <i>Medical Mycology</i> , 2020 , 58, 569-578	3.9	1
227	Black mold takes hold and story told. <i>Medical Mycology Case Reports</i> , 2020 , 29, 12-14	1.7	1
226	The robust and rapid role of molecular testing in precision fungal diagnostics: A case report. <i>Medical Mycology Case Reports</i> , 2020 , 27, 77-80	1.7	8
225	Assessing the virulence of <i>Cryptococcus neoformans</i> causing meningitis in HIV infected and uninfected patients in Vietnam. <i>Medical Mycology</i> , 2020 , 58, 1149-1161	3.9	4
224	Combination Therapy for Invasive Fungal Infections. <i>Current Fungal Infection Reports</i> , 2020 , 14, 40-49	1.4	17
223	Complete Genome Sequences for Two Clinical Isolates from Northern and Southern Vietnam. <i>Microbiology Resource Announcements</i> , 2020 , 9,	1.3	1
222	168. Efficacy of the Novel gwt1 Inhibitor APX2039 in a Rabbit Model of cryptococcus Meningitis. <i>Open Forum Infectious Diseases</i> , 2020 , 7, S213-S213	1	
221	The longitudinal health economic impact of viral encephalitis in the United States. <i>Journal of Medical Microbiology</i> , 2020 , 69, 270-279	3.2	4
220	Landscape of gene expression variation of natural isolates of in response to biologically relevant stresses. <i>Microbial Genomics</i> , 2020 , 6,	4.4	12
219	A case of CNS aspergillosis in a patient with chronic lymphocytic leukemia on first-line ibrutinib therapy. <i>Medical Mycology Case Reports</i> , 2020 , 27, 17-21	1.7	5
218	Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. <i>Clinical Infectious Diseases</i> , 2020 , 71, 1367-1376	11.6	607

217	Occult Infection Unveiled by the Novel Mp1p Antigen Detection Assay. <i>Open Forum Infectious Diseases</i> , 2020 , 7, ofaa502	1	5
216	Core Recommendations for Antifungal Stewardship: A Statement of the Mycoses Study Group Education and Research Consortium. <i>Journal of Infectious Diseases</i> , 2020 , 222, S175-S198	7	39
215	Emerging Issues in Antifungal Resistance. <i>Infectious Disease Clinics of North America</i> , 2020 , 34, 921-943	6.5	9
214	Invasive Fungal Infection After Lung Transplantation: Epidemiology in the Setting of Antifungal Prophylaxis. <i>Clinical Infectious Diseases</i> , 2020 , 70, 30-39	11.6	48
213	Genotypic diversity and clinical outcome of cryptococcosis in renal transplant recipients in Brazil. <i>Emerging Microbes and Infections</i> , 2019 , 8, 119-129	18.9	16
212	Pharmacodynamics of Isavuconazole in a Rabbit Model of Cryptococcal Meningoencephalitis. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	6
211	A Genome-Wide Functional Genomics Approach Identifies Susceptibility Pathways to Fungal Bloodstream Infection in Humans. <i>Journal of Infectious Diseases</i> , 2019 , 220, 862-872	7	13
210	Invasive Fungal Disease in the Transplant Population: An Overview 2019 , 519-541		1
209	<i>Cryptococcus neoformans</i> resists to drastic conditions by switching to viable but non-culturable cell phenotype. <i>PLoS Pathogens</i> , 2019 , 15, e1007945	7.6	13
208	2112. Voriconazole for Primary Prophylaxis: A Decade of Trends and Outcomes. <i>Open Forum Infectious Diseases</i> , 2019 , 6, S715-S715	1	78
207	Performance of the T2Bacteria Panel for Diagnosing Bloodstream Infections: A Diagnostic Accuracy Study. <i>Annals of Internal Medicine</i> , 2019 , 170, 845-852	8	35
206	Management of phaeohyphomycosis 2019 , 337-345		
205	Management of endemic mycoses 2019 , 317-323		
204	Management of mucormycoses 2019 , 357-362		
203	Management of cryptococcosis 2019 , 301-315		
202	Regulatory Mechanism of the Atypical AP-1-Like Transcription Factor Yap1 in <i>Cryptococcus neoformans</i> . <i>MSphere</i> , 2019 , 4,	5	2
201	1758. Epidemiology of Invasive Mycoplasma and Ureaplasma Infections Early after Lung Transplantation. <i>Open Forum Infectious Diseases</i> , 2019 , 6, S646-S646	1	2
200	Fluconazole Monotherapy Is a Suboptimal Option for Initial Treatment of Cryptococcal Meningitis Because of Emergence of Resistance. <i>MBio</i> , 2019 , 10,	7.8	22

199	Population Pharmacodynamics of Amphotericin B Deoxycholate for Disseminated Infection Caused by. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	3
198	How Clean Is the Linen at My Hospital? The Mucorales on Unclean Linen Discovery Study of Large United States Transplant and Cancer Centers. <i>Clinical Infectious Diseases</i> , 2019 , 68, 850-853	11.6	19
197	Real-world implications of QT prolongation in patients receiving voriconazole and amiodarone. <i>Journal of Antimicrobial Chemotherapy</i> , 2019 , 74, 228-233	5.1	4
196	Isavuconazole for treatment of invasive fungal diseases caused by more than one fungal species. <i>Mycoses</i> , 2018 , 61, 485-497	5.2	20
195	Isavuconazole for treatment of rare invasive fungal diseases. <i>Mycoses</i> , 2018 , 61, 518-533	5.2	26
194	Genome-wide analysis of the regulation of Cu metabolism in <i>Cryptococcus neoformans</i> . <i>Molecular Microbiology</i> , 2018 , 108, 473-494	4.1	19
193	Tolerability profile of the current antifungal armoury. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, i26-i32	5.1	30
192	Isavuconazole treatment for rare fungal diseases and for invasive aspergillosis in patients with renal impairment: Challenges and lessons of the VITAL trial. <i>Mycoses</i> , 2018 , 61, 420-429	5.2	17
191	Titan cells formation in <i>Cryptococcus neoformans</i> is finely tuned by environmental conditions and modulated by positive and negative genetic regulators. <i>PLoS Pathogens</i> , 2018 , 14, e1006982	7.6	65
190	Present and Future Therapy of Infections. <i>Journal of Fungi (Basel, Switzerland)</i> , 2018 , 4,	5.6	27
189	Pulmonary blastomycosis presenting as primary lung cancer. <i>BMC Infectious Diseases</i> , 2018 , 18, 336	4	4
188	The war on cryptococcosis: A Review of the antifungal arsenal. <i>Memórias Do Instituto Oswaldo Cruz</i> , 2018 , 113, e170391	2.6	37
187	and Evaluation of APX001A/APX001 and Other Gwt1 Inhibitors against <i>Cryptococcus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	58
186	On-demand release of <i>Candida albicans</i> biofilms from urinary catheters by mechanical surface deformation. <i>Biofouling</i> , 2018 , 34, 595-604	3.3	2
185	Prevalence, healthcare resource utilization and overall burden of fungal meningitis in the United States. <i>Journal of Medical Microbiology</i> , 2018 , 67, 215-227	3.2	26
184	Phenotypic Variability Correlates with Clinical Outcome in Isolates Obtained from Botswanan HIV/AIDS Patients. <i>MBio</i> , 2018 , 9,	7.8	24
183	Novel Treatment of Cryptococcal Meningitis via Neurapheresis Therapy. <i>Journal of Infectious Diseases</i> , 2018 , 218, 1147-1154	7	20
182	Genomic characterization of recurrent mold infections in thoracic transplant recipients. <i>Transplant Infectious Disease</i> , 2018 , 20, e12935	2.7	2

181	Trehalose pathway as an antifungal target. <i>Virulence</i> , 2017 , 8, 143-149	4.7	34
180	The Case for Adopting the "Species Complex" Nomenclature for the Etiologic Agents of Cryptococcosis. <i>MSphere</i> , 2017 , 2,	5	185
179	What Can the Clinical Mycology Laboratory Do for Clinicians Today and Tomorrow?. <i>Current Clinical Microbiology Reports</i> , 2017 , 4, 96-105	3.1	1
178	Experimental Models of Short Courses of Liposomal Amphotericin B for Induction Therapy for Cryptococcal Meningitis. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	18
177	The antifungal pipeline: a reality check. <i>Nature Reviews Drug Discovery</i> , 2017 , 16, 603-616	64.1	360
176	Population genomics and the evolution of virulence in the fungal pathogen. <i>Genome Research</i> , 2017 , 27, 1207-1219	9.7	85
175	Fungi that Infect Humans. <i>Microbiology Spectrum</i> , 2017 , 5,	8.9	87
174	Emergence of the Molds Other than Aspergillus in Immunocompromised Patients. <i>Clinics in Chest Medicine</i> , 2017 , 38, 555-573	5.3	7
173	Microevolution of Serial Clinical Isolates of var. and. <i>MBio</i> , 2017 , 8,	7.8	44
172	Central Role of the Trehalose Biosynthesis Pathway in the Pathogenesis of Human Fungal Infections: Opportunities and Challenges for Therapeutic Development. <i>Microbiology and Molecular Biology Reviews</i> , 2017 , 81,	13.2	51
171	Novel Agents and Drug Targets to Meet the Challenges of Resistant Fungi. <i>Journal of Infectious Diseases</i> , 2017 , 216, S474-S483	7	103
170	Disseminated Cryptococcosis With Brain Involvement in Patients With Chronic Lymphoid Malignancies on Ibrutinib. <i>Open Forum Infectious Diseases</i> , 2017 , 4, ofw261	1	40
169	Feasibility of Neurapheresis as a Therapy for Multidrug Resistant Gram-negative Bacterial Meningitis. <i>Open Forum Infectious Diseases</i> , 2017 , 4, S480-S481	1	3
168	In Vitro Characterization of the Neurapheresis System for the Treatment of Cryptococcal Meningitis. <i>Open Forum Infectious Diseases</i> , 2017 , 4, S481-S481	1	2
167	Structural and Studies on Trehalose-6-Phosphate Synthase from Pathogenic Fungi Provide Insights into Its Catalytic Mechanism, Biological Necessity, and Potential for Novel Antifungal Drug Design. <i>MBio</i> , 2017 , 8,	7.8	14
166	Reply to Argülles. <i>Virulence</i> , 2017 , 8, 239	4.7	1
165	Tracing Genetic Exchange and Biogeography of var. at the Global Population Level. <i>Genetics</i> , 2017 , 207, 327-346	4	57
164	Efficient, Cost-Effective, High-Throughput, Multilocus Sequencing Typing (MLST) Method, NGMLST, and the Analytical Software Program MLSTEZ. <i>Methods in Molecular Biology</i> , 2017 , 1492, 197-202	1.4	2

163	Curious Crosses: Injection-Induced Lesions. <i>American Journal of Medicine</i> , 2017 , 130, 31-33	2.4	1
162	Comparing outcomes of early, late, and non-surgical management of intraspinal abscess. <i>Journal of Clinical Neuroscience</i> , 2017 , 36, 64-71	2.2	9
161	Efficacy of Oral APX001 in a Murine Model of Cryptococcal Meningitis. <i>Open Forum Infectious Diseases</i> , 2017 , 4, S478-S478	1	5
160	Fungi that Infect Humans 2017 , 811-843		3
159	QTc Prolongation in Patients Receiving Triazoles and Amiodarone. <i>Open Forum Infectious Diseases</i> , 2017 , 4, S84-S84	1	1
158	An integrative genomics approach identifies novel pathways that influence candidaemia susceptibility. <i>PLoS ONE</i> , 2017 , 12, e0180824	3.7	17
157	Drug Resistance in Cryptococcosis 2017 , 1119-1140		4
156	The current treatment landscape: other fungal diseases (cryptococcosis, fusariosis and mucormycosis). <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, ii31-ii36	5.1	12
155	Simple Strategy for Taming Membrane-Disrupting Antibiotics. <i>Bioconjugate Chemistry</i> , 2016 , 27, 2850-2853	6.3	6
154	The Zinc Finger Protein Mig1 Regulates Mitochondrial Function and Azole Drug Susceptibility in the Pathogenic Fungus <i>Cryptococcus neoformans</i> . <i>MSphere</i> , 2016 , 1,	5	23
153	Structures of trehalose-6-phosphate phosphatase from pathogenic fungi reveal the mechanisms of substrate recognition and catalysis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016 , 113, 7148-53	11.5	37
152	CXCR1-mediated neutrophil degranulation and fungal killing promote <i>Candida</i> clearance and host survival. <i>Science Translational Medicine</i> , 2016 , 8, 322ra10	17.5	47
151	Cryptococcosis. <i>Infectious Disease Clinics of North America</i> , 2016 , 30, 179-206	6.5	302
150	Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. <i>Lancet Infectious Diseases</i> , 2016 , 16, 828-837	25.5	382
149	A Novel Therapeutic Approach for Cryptococcal Meningitis. <i>Open Forum Infectious Diseases</i> , 2016 , 3,	1	3
148	Familial Adenomatous Polyposis Manifesting as Endocarditis: A Case Report and Review of the Association of with Underlying Gastrointestinal Disease. <i>Case Reports in Infectious Diseases</i> , 2016 , 2016, 5805326	0.9	4
147	Copy number variation contributes to cryptic genetic variation in outbreak lineages of <i>Cryptococcus gattii</i> from the North American Pacific Northwest. <i>BMC Genomics</i> , 2016 , 17, 700	4.5	25
146	Repeated therapeutic lumbar punctures in cryptococcal meningitis - necessity and/or opportunity?. <i>Current Opinion in Infectious Diseases</i> , 2016 , 29, 539-545	5.4	16

145	Cases of disseminated cryptococcosis in intravenous drug abusers without HIV infection: A new risk factor?. <i>Medical Mycology Case Reports</i> , 2016 , 14, 17-19	1.7	14
144	Isavuconazole Treatment of Cryptococcosis and Dimorphic Mycoses. <i>Clinical Infectious Diseases</i> , 2016 , 63, 356-62	11.6	125
143	Intracellular Action of a Secreted Peptide Required for Fungal Virulence. <i>Cell Host and Microbe</i> , 2016 , 19, 849-64	23.4	59
142	Genetic Susceptibility to Fungal Infections: What is in the Genes?. <i>Current Clinical Microbiology Reports</i> , 2016 , 3, 81-91	3.1	26
141	Azole antifungals: 35 years of invasive fungal infection management. <i>Expert Review of Anti-Infective Therapy</i> , 2015 , 13, 787-98	5.5	111
140	Scedosporium apioserum infection of the "Native" valve: Fungal endocarditis in an orthotopic heart transplant recipient. <i>Medical Mycology Case Reports</i> , 2015 , 9, 34-6	1.7	7
139	Live Imaging of Host-Parasite Interactions in a Zebrafish Infection Model Reveals Cryptococcal Determinants of Virulence and Central Nervous System Invasion. <i>MBio</i> , 2015 , 6, e01425-15	7.8	49
138	Taming Amphotericin B. <i>Bioconjugate Chemistry</i> , 2015 , 26, 2021-4	6.3	24
137	Cryptococcosis diagnosis and treatment: What do we know now. <i>Fungal Genetics and Biology</i> , 2015 , 78, 49-54	3.9	145
136	Comparative analyses of clinical and environmental populations of <i>Cryptococcus neoformans</i> in Botswana. <i>Molecular Ecology</i> , 2015 , 24, 3559-71	5.7	38
135	AMBITION-cm: intermittent high dose AmBisome on a high dose fluconazole backbone for cryptococcal meningitis induction therapy in sub-Saharan Africa: study protocol for a randomized controlled trial. <i>Trials</i> , 2015 , 16, 276	2.8	21
134	The RIG-I-like helicase receptor MDA5 (IFIH1) is involved in the host defense against <i>Candida</i> infections. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2015 , 34, 963-974	5.3	46
133	Next generation multilocus sequence typing (NGMLST) and the analytical software program MLSTEZ enable efficient, cost-effective, high-throughput, multilocus sequencing typing. <i>Fungal Genetics and Biology</i> , 2015 , 75, 64-71	3.9	27
132	Update on epidemiology of and preventive strategies for invasive fungal infections in cancer patients. <i>Clinical Infectious Diseases</i> , 2014 , 59 Suppl 5, S352-5	11.6	40
131	Molecular Typing of the <i>Cryptococcus neoformans</i> / <i>Cryptococcus gattii</i> Species Complex 2014 , 327-357		15
130	ImmunoChip SNP array identifies novel genetic variants conferring susceptibility to candidaemia. <i>Nature Communications</i> , 2014 , 5, 4675	17.4	62
129	Analysis of the genome and transcriptome of <i>Cryptococcus neoformans</i> var. <i>grubii</i> reveals complex RNA expression and microevolution leading to virulence attenuation. <i>PLoS Genetics</i> , 2014 , 10, e1004261 ⁶		260
128	Future strategies for the treatment of cryptococcal meningoencephalitis in pediatric patients. <i>Expert Opinion on Orphan Drugs</i> , 2014 , 2, 245-257	1.1	

127	The <i>Cryptococcus neoformans</i> transcriptome at the site of human meningitis. <i>MBio</i> , 2014 , 5, e01087-13	7.8	85
126	Phase 1b study of new posaconazole tablet for prevention of invasive fungal infections in high-risk patients with neutropenia. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 5758-65	5.9	92
125	Very low levels of 25-hydroxyvitamin D are not associated with immunologic changes or clinical outcome in South African patients with HIV-associated cryptococcal meningitis. <i>Clinical Infectious Diseases</i> , 2014 , 59, 493-500	11.6	9
124	Inkjet Printing of Amphotericin B onto Biodegradable Microneedles Using Piezoelectric Inkjet Printing. <i>Jom</i> , 2013 , 65, 525-533	2.1	31
123	Functional genomics identifies type I interferon pathway as central for host defense against <i>Candida albicans</i> . <i>Nature Communications</i> , 2013 , 4, 1342	17.4	119
122	Fungal diagnosis: how do we do it and can we do better?. <i>Current Medical Research and Opinion</i> , 2013 , 29 Suppl 4, 3-11	2.5	72
121	Brain inositol is a novel stimulator for promoting <i>Cryptococcus</i> penetration of the blood-brain barrier. <i>PLoS Pathogens</i> , 2013 , 9, e1003247	7.6	54
120	Posaconazole exhibits in vitro and in vivo synergistic antifungal activity with caspofungin or FK506 against <i>Candida albicans</i> . <i>PLoS ONE</i> , 2013 , 8, e57672	3.7	43
119	CX3CR1-dependent renal macrophage survival promotes <i>Candida</i> control and host survival. <i>Journal of Clinical Investigation</i> , 2013 , 123, 5035-51	15.9	153
118	The impact of the host on fungal infections. <i>American Journal of Medicine</i> , 2012 , 125, S39-51	2.4	64
117	Comparison and temporal trends of three groups with cryptococcosis: HIV-infected, solid organ transplant, and HIV-negative/non-transplant. <i>PLoS ONE</i> , 2012 , 7, e43582	3.7	122
116	Surfactant protein D facilitates <i>Cryptococcus neoformans</i> infection. <i>Infection and Immunity</i> , 2012 , 80, 2444-53	3.7	31
115	Human genetic susceptibility to <i>Candida</i> infections. <i>Medical Mycology</i> , 2012 , 50, 785-94	3.9	30
114	IRIS and Fungal Infections: What Have We Learned?. <i>Current Fungal Infection Reports</i> , 2012 , 6, 1-10	1.4	1
113	Toll-like receptor 1 polymorphisms increase susceptibility to candidemia. <i>Journal of Infectious Diseases</i> , 2012 , 205, 934-43	7	102
112	Cytokine gene polymorphisms and the outcome of invasive candidiasis: a prospective cohort study. <i>Clinical Infectious Diseases</i> , 2012 , 54, 502-10	11.6	61
111	The triple threat of cryptococcosis: it's the body site, the strain, and/or the host. <i>MBio</i> , 2012 , 3,	7.8	21
110	Invasive mycoses: evolving challenges and opportunities in antifungal therapy (multimedia activity). <i>American Journal of Medicine</i> , 2011 , 124, S2-3	2.4	24

109	Addressing current medical needs in invasive fungal infection prevention and treatment with new antifungal agents, strategies and formulations. <i>Expert Opinion on Emerging Drugs</i> , 2011 , 16, 559-586	3.7	42
108	<i>Cryptococcus neoformans</i> requires a functional glycolytic pathway for disease but not persistence in the host. <i>MBio</i> , 2011 , 2, e00103-11	7.8	71
107	Trehalose 6-phosphate phosphatase is required for cell wall integrity and fungal virulence but not trehalose biosynthesis in the human fungal pathogen <i>Aspergillus fumigatus</i> . <i>Molecular Microbiology</i> , 2010 , 77, 891-911	4.1	85
106	Survival defects of <i>Cryptococcus neoformans</i> mutants exposed to human cerebrospinal fluid result in attenuated virulence in an experimental model of meningitis. <i>Infection and Immunity</i> , 2010 , 78, 4213-237	3.7	43
105	Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. <i>Clinical Infectious Diseases</i> , 2010 , 50, 291-322	11.6	1683
104	Blood gene expression signatures predict invasive candidiasis. <i>Science Translational Medicine</i> , 2010 , 2, 21ra17	17.5	34
103	Use of Antifungal Combination Therapy: Agents, Order, and Timing. <i>Current Fungal Infection Reports</i> , 2010 , 4, 87-95	1.4	63
102	The trehalose synthesis pathway is an integral part of the virulence composite for <i>Cryptococcus gattii</i> . <i>Infection and Immunity</i> , 2009 , 77, 4584-96	3.7	75
101	Human dectin-1 deficiency and mucocutaneous fungal infections. <i>New England Journal of Medicine</i> , 2009 , 361, 1760-7	59.2	573
100	Metabolic adaptation in <i>Cryptococcus neoformans</i> during early murine pulmonary infection. <i>Molecular Microbiology</i> , 2008 , 69, 1456-75	4.1	118
99	Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. <i>Clinical Infectious Diseases</i> , 2008 , 46, 1813-21	11.6	3744
98	Antimicrobial resistance: resistance to antifungal agents: mechanisms and clinical impact. <i>Clinical Infectious Diseases</i> , 2008 , 46, 120-8	11.6	395
97	Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. <i>Clinical Infectious Diseases</i> , 2008 , 47, 674-83	11.6	308
96	Plasminogen alleles influence susceptibility to invasive aspergillosis. <i>PLoS Genetics</i> , 2008 , 4, e1000101	6	131
95	Management of cryptococcosis: how are we doing?. <i>PLoS Medicine</i> , 2007 , 4, e47	11.6	8
94	Fatty acid synthesis is essential for survival of <i>Cryptococcus neoformans</i> and a potential fungicidal target. <i>Antimicrobial Agents and Chemotherapy</i> , 2007 , 51, 3537-45	5.9	33
93	Protection against cryptococcosis by using a murine gamma interferon-producing <i>Cryptococcus neoformans</i> strain. <i>Infection and Immunity</i> , 2007 , 75, 1453-62	3.7	126
92	Characterization and regulation of the trehalose synthesis pathway and its importance in the pathogenicity of <i>Cryptococcus neoformans</i> . <i>Infection and Immunity</i> , 2006 , 74, 5877-87	3.7	120

91	Cost-Effectiveness of Posaconazole Versus Standard Azole Therapy in the Prevention of Invasive Fungal Infections among High-Risk Neutropenic Patients in the U.S.. <i>Blood</i> , 2006 , 108, 3311-3311	2.2	0
90	Posaconazole. <i>Drugs</i> , 2005 , 65, 1568-1569	12.1	2
89	<i>Cryptococcus neoformans</i> : a sugar-coated killer with designer genes. <i>FEMS Immunology and Medical Microbiology</i> , 2005 , 45, 395-404		82
88	Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis. <i>Antimicrobial Agents and Chemotherapy</i> , 2005 , 49, 952-8	5.9	182
87	Treatment of non-Aspergillus moulds in immunocompromised patients, with amphotericin B lipid complex. <i>Clinical Infectious Diseases</i> , 2005 , 40 Suppl 6, S401-8	11.6	120
86	Design of aerosolized amphotericin b formulations for prophylaxis trials among lung transplant recipients. <i>Clinical Infectious Diseases</i> , 2004 , 39 Suppl 4, S207-10	11.6	26
85	Combination antifungal therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2004 , 48, 693-715	5.9	412
84	Management of invasive mycoses in hematology patients: current approaches. <i>Oncology</i> , 2004 , 18, 5-14	1.8	2
83	Use of newer antifungal therapies in clinical practice: what do the data tell us?. <i>Oncology</i> , 2004 , 18, 15-23	1.8	1
82	Antifungal resistance: the clinical front. <i>Oncology</i> , 2004 , 18, 15-22	1.8	5
81	Voriconazole treatment for less-common, emerging, or refractory fungal infections. <i>Clinical Infectious Diseases</i> , 2003 , 36, 1122-31	11.6	562
80	Regulation of cytochrome c oxidase subunit 1 (COX1) expression in <i>Cryptococcus neoformans</i> by temperature and host environment. <i>Microbiology (United Kingdom)</i> , 2003 , 149, 1041-1049	2.9	32
79	Cryptococcosis. <i>Infectious Disease Clinics of North America</i> , 2002 , 16, 837-74, v-vi	6.5	314
78	Antisense repression in <i>Cryptococcus neoformans</i> as a laboratory tool and potential antifungal strategy. <i>Microbiology (United Kingdom)</i> , 2002 , 148, 213-219	2.9	43
77	Fungal infections of the bones and joints. <i>Current Infectious Disease Reports</i> , 2001 , 3, 450-460	3.9	16
76	Extracellular phospholipase activity is a virulence factor for <i>Cryptococcus neoformans</i> . <i>Molecular Microbiology</i> , 2001 , 39, 166-75	4.1	286
75	Identification and characterization of the <i>Cryptococcus neoformans</i> phosphomannose isomerase-encoding gene, MAN1, and its impact on pathogenicity. <i>Molecular Microbiology</i> , 2001 , 40, 610-20	4.1	80
74	Cyclic AMP-dependent protein kinase controls virulence of the fungal pathogen <i>Cryptococcus neoformans</i> . <i>Molecular and Cellular Biology</i> , 2001 , 21, 3179-91	4.8	288

73	RAS1 regulates filamentation, mating and growth at high temperature of <i>Cryptococcus neoformans</i> . <i>Molecular Microbiology</i> , 2000 , 36, 352-65	4.1	188
72	Identification and characterization of a highly conserved calcineurin binding protein, CBP1/calciressin, in <i>Cryptococcus neoformans</i> . <i>EMBO Journal</i> , 2000 , 19, 3618-29	13	136
71	Urease as a virulence factor in experimental cryptococcosis. <i>Infection and Immunity</i> , 2000 , 68, 443-8	3.7	395
70	New potential targets for antifungal development. <i>Expert Opinion on Therapeutic Targets</i> , 2000 , 4, 265-296		15
69	Association of plasma levels of human immunodeficiency virus type 1 RNA and oropharyngeal <i>Candida</i> colonization. <i>Journal of Infectious Diseases</i> , 1999 , 180, 534-7	7	59
68	Drug resistance in <i>Cryptococcus neoformans</i> . <i>Drug Resistance Updates</i> , 1999 , 2, 259-269	23.2	72
67	Topoisomerase I is essential in <i>Cryptococcus neoformans</i> : role in pathobiology and as an antifungal target. <i>Genetics</i> , 1999 , 152, 167-78	4	62
66	The STE12alpha homolog is required for haploid filamentation but largely dispensable for mating and virulence in <i>Cryptococcus neoformans</i> . <i>Genetics</i> , 1999 , 153, 1601-15	4	115
65	Morphologic criteria for the preliminary identification of <i>Fusarium</i> , <i>Paecilomyces</i> , and <i>Acremonium</i> species by histopathology. <i>American Journal of Clinical Pathology</i> , 1998 , 109, 45-54	1.9	150
64	1998 ,		592
63	Antifungal resistance trends towards the year 2000. Implications for therapy and new approaches. <i>Drugs</i> , 1997 , 54, 657-78	12.1	113
62	Adverse drug reactions to systemic antifungals. Prevention and management. <i>Drug Safety</i> , 1992 , 7, 323-331	6.3	55
61	Deferoxamine treatment as a risk factor for zygomycete infection. <i>Journal of Infectious Diseases</i> , 1989 , 159, 151-2	7	21
60	Cryptococcal meningitis with normal cerebrospinal fluid. <i>Journal of Infectious Diseases</i> , 1989 , 160, 912	7	13
59	Cryptococcosis. <i>Infectious Disease Clinics of North America</i> , 1989 , 3, 77-102	6.5	86
58	<i>Mycobacterium avium</i> -intracellulare complex infections in the acquired immunodeficiency syndrome. <i>Journal of Electron Microscopy Technique</i> , 1988 , 8, 105-13		5
57	Retrospective review of amphotericin B use in a tertiary-care medical center. <i>American Journal of Health-System Pharmacy</i> , 1987 , 44, 1353-1357	2.2	
56	Potential value of cefoperazone in bacterial meningitis: experimental studies. <i>Drugs</i> , 1981 , 22 Suppl 1, 60-4	12.1	6

55	Fungal Molecular Pathogenesis: What Can It Do and Why Do We Need It?1-11	7
54	<i>Cryptococcus neoformans</i> : a Sugar-Coated Killer279-303	6
53	Systematics of the Genus <i>Cryptococcus</i> and Its Type Species <i>C. neoformans</i> 1-15	11
52	The Mating-Type Locus of <i>Cryptococcus</i> : Evolution of Gene Clusters Governing Sex Determination and Sexual Reproduction from the Phylogenomic Perspective139-149	6
51	A Role for Mating in <i>Cryptococcal</i> Virulence167-174	2
50	Sensing Extracellular Signals in <i>Cryptococcus neoformans</i> 175-187	1
49	Drug Resistance in <i>Cryptococcus</i> : Epidemiology and Molecular Mechanisms203-216	2
48	Signaling Cascades and Enzymes as <i>Cryptococcus</i> Virulence Factors217-234	1
47	Environmental Niches for <i>Cryptococcus neoformans</i> and <i>Cryptococcus gattii</i> 235-259	15
46	The History of <i>Cryptococcus</i> and <i>Cryptococcosis</i> 17-26	5
45	<i>Cryptococcosis</i> in Africa269-285	3
44	<i>Cryptococcosis</i> in Asia287-297	2
43	Sexual Reproduction of <i>Cryptococcus gattii</i> : a Population Genetics Perspective299-311	1
42	The Emergence of <i>Cryptococcus gattii</i> Infections on Vancouver Island and Expansion in the Pacific Northwest313-325	13
41	Hybridization and Its Importance in the <i>Cryptococcus</i> Species Complex359-370	2
40	Biosynthesis and Genetics of the <i>Cryptococcus</i> Capsule27-41	2
39	<i>Cryptococcus</i> Interactions with Innate Cytotoxic Lymphocytes417-427	1
38	Invasion of <i>Cryptococcus</i> into the Central Nervous System465-471	5

37	Cryptococcosis in Experimental Animals: Lessons Learned473-488	1
36	Veterinary Insights into Cryptococcosis Caused by <i>Cryptococcus neoformans</i> and <i>Cryptococcus gattii</i> 489-504	7
35	Cryptococcosis in Transplant Recipients505-514	1
34	Cryptococcosis in AIDS515-525	4
33	The Architecture and Antigenic Composition of the Polysaccharide Capsule43-54	6
32	Vaccines and Antibody Therapies from <i>Cryptococcus neoformans</i> to Melanoma537-546	1
31	Diagnostic Approach Based on Capsular Antigen, Capsule Detection, β Glucan, and DNA Analysis547-564	5
30	Public Health Importance of Cryptococcal Disease: Epidemiology, Burden, and Control585-593	4
29	Clinical Perspectives on <i>Cryptococcus neoformans</i> and <i>Cryptococcus gattii</i> : Implications for Diagnosis and Management595-606	13
28	Melanin: Structure, Function, and Biosynthesis in <i>Cryptococcus</i> 55-66	1
27	The Cell Wall of <i>Cryptococcus</i> 67-79	3
26	Sexual Reproduction of <i>Cryptococcus</i> 81-96	1
25	Population Structure and Ecology of <i>Cryptococcus neoformans</i> and <i>Cryptococcus gattii</i> 97-111	5
24	Introduction to the Pathogen1-27	2
23	Diagnosis and Laboratory Techniques381-405	6
22	Human Cryptococcosis407-456	10
21	Therapy of Cryptococcosis457-518	3
20	Prevention of Human Infection519-530	2

19	Ecology of <i>Cryptococcus neoformans</i> 41-70	9
18	Virulence Factors 145-176	6
17	Specific Immunity and Cytokines 223-269	3
16	Antifungal pharmacotherapy for invasive mould infections	1
15	Population genomics of <i>Cryptococcus neoformans</i> var. <i>grubii</i> reveals new biogeographic relationships and finely maps hybridization	2
14	Titan cells formation in <i>Cryptococcus neoformans</i> is finely tuned by environmental conditions and modulated by positive and negative genetic regulators	2
13	Fab-dimerized glycan-reactive antibodies neutralize HIV and are prevalent in humans and rhesus macaques	4
12	Phenotypic variability correlates with clinical outcome in <i>Cryptococcus</i> isolates obtained from Botswanan HIV/AIDS patients	1
11	Management of Cryptococcal Meningoencephalitis in Both Developed and Developing Countries 565-584	
10	Animal Models and Veterinary Aspects of Cryptococcosis 325-350	1
9	The Interaction of <i>Cryptococcus neoformans</i> with Host Macrophages and Neutrophils 371-385	
8	Pulmonary Innate and Adaptive Defenses against <i>Cryptococcus</i> 451-464	
7	Physical Defenses and Nonspecific Immunity 177-222	
6	Intracellular Replication and Exit Strategies 441-450	1
5	Population genomics and the evolution of virulence in the fungal pathogen <i>Cryptococcus neoformans</i>	1
4	Tissue Responses and Special Topics in Immunity 271-324	
3	Virulence Mechanisms of <i>Cryptococcus gattii</i> : Convergence and Divergence 189-201	
2	G-Protein Signaling Pathways: Regulating Morphogenesis and Virulence of <i>Cryptococcus</i> 151-165	

1 Acquired Humoral Immunity to *Cryptococcus neoformans* 397-408